Calgary, Alberta (ots/PRNewswire) - Resverlogix announced today that its lead drug RVX-208, a first in class ApoA-I production drug, illustrated positive effects on an important cognitive function and Alzheimer's Disease (AD) marker, plasma Amyloid beta 40 (Abeta40). This analysis was performed based on increasing evidence in the literature that the transport ...
Chicago, November 17 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix") announces its top line results of the ASSERT Phase 2 clinical trial which will be highlighted at the prestigious American Heart Association Scientific Sessions 2010 Late Breaking Clinical Trial session, by principal investigator Dr. ...
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that Mr. Kenneth Zuerblis has been appointed to the Company's Board of Directors. Recently Mr. Zuerblis served as the Chief Financial Officer and Senior Vice President of ImClone Systems Inc., prior to its acquisition by Eli Lilly. "I was initially attracted to Resverlogix because of RVX-208, its novel atherosclerosis ...
Hamburg and Calgary, Canada, June 22, 2010 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference being held in Hamburg, Germany. The presentation titled "RVX-208 given orally raises ...
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that the Board of Directors has elected Arthur J. Higgins, CEO of Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee, to the Board effective February 1, 2010. Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer HealthCare ...
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD). This study is chaired by Dr. Steven Nissen, MD, Chairman ...
Calgary, Canada (ots/PRNewswire) - - Powerful Effects Seen in all Subjects Including Those With Low HDL - Representing a Majority of Myocardial Infarct Patients TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that results from the Company's Phase ...
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top line results of the Company's Phase 1b/2a clinical trial for RVX-208, an oral small molecule in development ...
Calgary, Canada, November 10 (ots/PRNewswire) - - First in Class Drug Illustrates Early Signal of Transport of Key Amyloid Marker From Brain - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from ...
Calgary, Canada (ots/PRNewswire) - - Provides Shareholders With an Update on Strategic Review Activities On behalf of Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) the Board of Directors, due to the recent advancement of various discussions with third parties, feel it is prudent to update the market as to activities surrounding a previously announced strategic review process of January 25, 2007. ...
Calgary, Canada (ots/PRNewswire) - - Multiple Presentations Included Resverlogix Data - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Dr. Norman Wong presented key clinical data pertaining to its lead compound, RVX-208, at the European Society Cardiology (ESC) 2008 Congress in Munich. The presentation titled "RVX-208 a novel small ...
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low high-density lipoprotein (HDL) cholesterol has proceeded according to plan. "We are very excited about moving forward into this important 28-day study with RVX-208. Our previous clinical study ...
Calgary, Canada (ots/PRNewswire) - - RVX-208 is the Only Apo-Al/HDL Drug to be Highlighted Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Resverlogix's lead drug is featured prominently in an article titled "Emerging Antidyslipidemic Drugs", which appears in the current edition of Expert Opinion of Emerging Drugs, a well respected scientific journal for the ...
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp's ("Resverlogix" or the "Company") (TSX:RVX) novel lead ApoA-I drug candidate, RVX-208 has been selected as one of the top 10 most promising cardiovascular disease (CVD) drugs available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business ...
San Diego, California and Calgary, Canada (ots/PRNewswire) - - Findings Demonstrate Clear Trends of Proof of Principle of Reverse Cholesterol Transport in Human Volunteers SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today that it has completed the planned exploratory efficacy analysis of the data from the Phase I, 7 ...
Calgary, Canada (ots/PRNewswire) - - Phase 1a Study Objectives Were Met - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead drug candidate, RVX-208, which addresses the dyslipidemia market. "Initial results from the emerging data are very good," ...
Calgary, Canada (ots/PRNewswire) - - Resverlogix Sees Early Success and Expedites Phase 2 Plans TSX Exchange Symbol: RVX Resverlogix is pleased to announce preliminary data from the RVX-208 Phase 1 safety and pharmacokinetics study. Forty healthy volunteers have so far been treated of which sixteen have received multiple doses. As anticipated from the extensive Investigational New Drug toxicology studies no ...
Calgary, Canada (ots/PRNewswire) - - New Class of ApoA-I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small ...
Calgary, Canada, November 29 (ots/PRNewswire) - - ApoA-I Technology is Recognized for its Ability to Transform the Treatment of Cardiovascular Disease Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that the World Economic Forum has selected Resverlogix as a winner of the very prestigious Technology Pioneer Award in recognition of ...
Orlando, Florida, November 5 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208, at the American Heart Association Scientific Meetings. The presentation titled "Oral ...
Calgary, Canada (ots/PRNewswire) - - Novel ApoA-I/HDL Raising Drug, RVX-208, to be Featured in Oral Presentation Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that tommorrow it is making an oral presentation highlighting key scientific data of its lead clinical molecule, RVX-208, at the International Atherosclerosis Society (IAS) Workshop on HDL. The presentation titled "A novel drug that ...